Συμμετοχή σε διεθνείς πολυκεντρικές μελέτες (Appendix)
- Mann J, Julius S for the VALUE Trial Group. The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 7: 176-183, 1998. pdf
- Kjeldsen SE, Hedner T, Jamerson K, Julius S, Haley WE, Zabalgoitia M, Butt AR, Rahman SN, Hansson L. Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. Hypertension 31: 1014-1020, 1998. pdf
- Farsang C, Garcia-Puig J, Niegowska J, Baiz AQ, Vrijens F, Bortman G, Losartan ISH Investigators Group. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. J Hypertens 18: 795-801, 2000. pdf
- Kjeldsen SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, Laragh J, McInnes G, Smith B, Weber M, Zanchetti A, for the VALUE Trial Group. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Pressure 10 (2): 83-91, 2001.
- Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan of the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001 pdf
- Dahlof B, Degl'Innocnenti A, Elmfeldt D, Puig JC, Gundersen T, Hosie J, Januszewicz W, Lindstrom C-J, Magometschnigg D, Tanser P, Toutouzas P, Waeber B, Wiklund I. Felodipine-metaprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. Am J Hypertens 18: 1313-1319, 2005. pdf
- Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork A, Stolt P, Viskoper R, Widimsky J, Zanchetti A for the VALUE trial investigators. Effect of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 24: 1405-1412, 2006. pdf
- Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, for the AVOID Sudy Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358(23): 2433-2446, 2008 pdf
- Hutchison AJ, Laville M, on behalf of the SPD405-313 Lanthanum Study Group. Swithching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 23(11):3677-3684, 2008 pdf
- Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae D-W, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Gert Mayer G, McMahon AW, Parving H-H, Remuzzi G, Samuelsson O, Sonkodi S, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F, for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialyis. N Engl J Med 360(14); 1395-1407, 2009 pdf
- Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R; on behalf of the VALIGA study of the ERA-EDTA Immunonephrology Working Group. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. J Am Soc Nephrol. 2015 Feb 12. pii: ASN.2014070697.
- Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts IS, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, Ferrario F, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A; VALIGA study of the ERA-EDTA Immunonephrology Working Group. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014 Oct;86(4):828-36. doi: 10.1038/ki.2014.63. Epub 2014 Apr 2.
